2024
Advancements in risk stratification and management strategies in primary cardiovascular prevention
BARKAS, Fotios, Yusuf Ziya SENER, Pelin Arabacilar GOLFOROUSH, Azin KHEIRKHAH, Elena RODRIGUEZ-SANCHEZ et. al.Základní údaje
Originální název
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Autoři
BARKAS, Fotios, Yusuf Ziya SENER, Pelin Arabacilar GOLFOROUSH, Azin KHEIRKHAH, Elena RODRIGUEZ-SANCHEZ, Jan NOVÁK (203 Česká republika, domácí), Maria APELLANIZ-RUIZ, Ralph Kwame AKYEA, Vanessa BIANCONI, Alexandr CEASOVSCHIH, Ying Jie CHEE, Mariia CHERSKA, Joana Rita CHORA, Mario ORIA, Nadiia DEMIKHOVA, Duygu Kocyigit BURUNKAYA, Antoine RIMBERT, Chiara MACCHI, Krishnaraj RATHOD, Lynn ROTH, Vasily SUKHORUKOV, Svetlana STOICA, Roberto SCICALI, Tatyana STOROZHENKO, Jamol UZOKOV, Maria Giovanna LUPO, Emiel P C VAN DER VORST a Florentina PORSCH
Vydání
Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2024, 0021-9150
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.300 v roce 2022
Organizační jednotka
Lékařská fakulta
UT WoS
001250139600001
Klíčová slova anglicky
Cardiovascular disease; Atherosclerosis; Risk stratification; Plaque regression; Primary prevention
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 12. 7. 2024 08:54, Mgr. Tereza Miškechová
Anotace
V originále
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, highlighting the urgent need for advancements in risk assessment and management strategies. Although significant progress has been made recently, identifying and managing apparently healthy individuals at a higher risk of developing atherosclerosis and those with subclinical atherosclerosis still poses significant challenges. Traditional risk assessment tools have limitations in accurately predicting future events and fail to encompass the complexity of the atherosclerosis trajectory. In this review, we describe novel approaches in biomarkers, genetics, advanced imaging techniques, and artificial intelligence that have emerged to address this gap. Moreover, polygenic risk scores and imaging modalities such as coronary artery calcium scoring, and coronary computed tomography angiography offer promising avenues for enhancing primary cardiovascular risk stratification and personalised intervention strategies. On the other hand, interventions aiming against atherosclerosis development or promoting plaque regression have gained attention in primary ASCVD prevention. Therefore, the potential role of drugs like statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, omega -3 fatty acids, antihypertensive agents, as well as glucose -lowering and anti-inflammatory drugs are also discussed. Since findings regarding the efficacy of these interventions vary, further research is still required to elucidate their mechanisms of action, optimize treatment regimens, and determine their long-term effects on ASCVD outcomes. In conclusion, advancements in strategies addressing atherosclerosis prevention and plaque regression present promising avenues for enhancing primary ASCVD prevention through personalised approaches tailored to individual risk profiles. Nevertheless, ongoing research efforts are imperative to refine these strategies further and maximise their effectiveness in safeguarding cardiovascular health.